Objective: The 2013 American College of Cardiology/American Heart Association lipid management guidelines recommend high-intensity statins for all patients #75 years old with chronic limb-threatening ischemia (CLTI) and moderateintensity statins for CLTI patients >75 years old without contraindications or on dialysis, but these recommendations are based primarily on coronary and stroke data. We aimed to validate these guidelines in patients with CLTI and to assess current adherence to these recommendations.
Peripheral arterial disease (PAD) is the manifestation of atherosclerosis in the extremities. Epidemiologic studies demonstrate that PAD afflicts one in five adults older than 65 years. 1, 2 Although many patients with PAD are asymptomatic at time of diagnosis, manifestations of the disease range from intermittent claudication to limb-threatening ischemia. Chronic limb-threatening ischemia (CLTI), the infrainguinal equivalent of a myocardial infarction or cerebrovascular accident, is the most devastating form of PAD and afflicts up to 1% of the population. 3 CLTIddefined as ischemia with rest pain, ulceration, or gangrenedcarries with it significant morbidity and mortality. Recent studies demonstrate a 30% rate of death or major adverse limb event (MALE) at 1 year even after successful revascularization. 4 Mortality rates remain as high as 25% per year in modern series, with 1-year amputation rates of 25%. 5 Significant advances have been made during the past 20 years in the medical management of atherosclerosis in the coronary and cerebrovascular circulations. Antiplatelet agents, beta blockers, antihypertensives, and statin therapy are now mainstays of therapy, supported by a rich evidence base. [4] [5] [6] [7] [8] In 2013, the American College of Cardiology (ACC) and the American Heart Association (AHA) published an update to their lipid management guidelines. They made two key recommendations: with the exception of patients receiving hemodialysis and those with contraindications or allergies, all patients with CLTI older than 75 years should be taking a moderate-intensity statin, and those younger than 75 years should be taking a high-intensity statin. 9 These new guidelines were unique in that they replaced targeted blood cholesterol levels with recommended intensity of statin therapy, and their target population was expanded to include patients with PAD. These recommendations are supported by a robust evidence base in patients with atherosclerotic disease in the coronary and cerebrovascular circulations. 9 In contrast, there is significantly less evidence for the use of these therapiesdespecially the intensity of therapydin patients with peripheral vascular disease. Studies from the Vascular Quality Initiative (VQI) and the REduction of Atherothrombosis for Continued Health (REACH) registries demonstrated an 18% higher rate of survival for PAD patients taking statins compared with those not prescribed statins, but these studies lack any information about intensity of therapy. 10, 11 Unfortunately, despite these guidelines (and probably at least in part because of the dearth of evidence), statins remain underused in PAD. A study of Danish registries found that only about half of all patients with PAD were taking a statin, and only 62% of vascular patients in the VQI were prescribed a statin and an antiplatelet agent. 11, 12 To our knowledge, there are no data on the rate of adherence to these recent guidelines or the relationship between their application and outcomes in a vascular population. Therefore, our goal was to assess the application of the recent ACC/AHA lipid management guidelines to the CLTI population.
METHODS
Subjects. We performed a retrospective cohort study of all patients with CLTI who underwent a first-time revascularization procedure between 2005 and 2014 at a single institution. Patients were identified through the review of online booking, institutional Vascular Study Group of New England data, and billing data. Patient charts were then reviewed to confirm the procedures performed. Patients on hemodialysis were excluded. The Beth Israel Deaconess Medical Center Institutional Review Board approved this study and waived the need for consent of the patient because of the retrospective nature of the design.
Statins. Postoperative statin use and intensity were recorded from the discharge medication lists from the index procedure. Statin intensity was classified according to ACC/AHA guidelines, which recommend highintensity statins in patients with CLTI #75 years old and moderate-intensity in those >75 years old (Table I) . Patients on hemodialysis (n ¼ 252) were excluded as there were no applicable guidelines, and patients taking simvastatin 80 mg (n ¼ 51) were excluded from the primary analysis as this is no longer a recommended dose and was therefore left out of the guidelines.
Outcomes. The primary outcome was death, and the secondary outcome was MALE. MALEs included amputation and major reintervention, defined as creation of a new bypass graft, a jump/interposition graft revision, surgical thrombectomy with or without surgical patch angioplasty, and thrombectomy of an occluded graft or arterial segment using pharmacologic or mechanical thrombolysis. Only major amputations were considered (defined as proximal to the ankle joint). Limb events and interventions were ascertained through chart review, and death was ascertained through chart review and the Social Security Death Index.
To address the problem of repeated measures from treating both limbs independently, if a patient underwent an intervention on one limb and later underwent a contralateral intervention for CLTI, the initial leg was censored at the entry date of the second limb.
Statistical analysis.
We assessed the association between discharge on any statin therapy and no statin therapy as well as the association of the intensity of statin therapy with the primary and secondary outcomes.
Categorical variables were compared using Pearson c 2 and Fisher exact tests. Continuous variables were compared using the Wilcoxon rank sum test. Univariate survival analysis was carried out with the log-rank test. Cox proportional hazards models were constructed to examine the association between adherence to guidelines and rates of MALE or death. We constructed a propensity score modeling the odds of receiving treatment with guideline-recommended intensity of statin therapy in a logistic regression model to account for nonrandom assignment to treatment. Covariates were generously introduced into the model, which included age, gender, race, hypertension, renal disease, coronary artery disease, diabetes, chronic obstructive pulmonary disease, smoking, heart failure, stroke, procedure year, indication for procedure (rest pain, ulceration, or gangrene), index procedure (endovascular vs open), and preoperative ambulatory status. After computing propensity scores, we assessed covariate balance and overlap of the distributions across treatment groups using the "teffects overlap" and "tebalance" commands in Stata version 14.2 (StataCorp LP, College Station, Tex). We used Cox proportional hazard regression for our outcome models. The Cox models were adjusted for the propensity scores (entered as a continuous covariate), and to further reduce the potential for residual confounding, the models were also adjusted for potential confounders chosen a priori on the basis of their plausible confounding effects. A propensity score was not constructed for the analysis of patients taking statins compared with those not taking statins as no score could be constructed that had sufficient overlap.
In a sensitivity analysis, we included the patients taking 80 mg of simvastatin, classifying them as high-intensity statin therapy. Because this was a single-center study, we also examined the association between intensity of statin therapy and loss to follow-up to assess for any potential bias in our results.
All statistical analyses were performed using Stata 14.2.
RESULTS

Baseline characteristics
We identified 1336 limbs from 1195 patients. After excluding patients on hemodialysis (n ¼ 252) and those taking 80 mg of simvastatin (n ¼ 51) as well as 14 with missing prescription data, there were 1019 limbs from 931 patients, with a median follow-up of 380 days (interquartile range, 58-1113). Baseline characteristics are presented in Table II . Patients on the recommended intensity of statin therapy had significantly more comorbidities compared with those who were not on their recommended intensity, with higher rates of preoperative statin use, coronary artery disease, chronic kidney disease, stroke, atrial fibrillation, congestive heart failure, and coronary artery bypass grafting and lower rates of smoking and preoperative ambulation (all P < .05). However, in the subgroup of patients older than 75 years, there were no differences that reached statistical significance in the baseline characteristics of the patients on recommended intensity of therapy and those who were not.
Adherence to guidelines
Overall, 77% of the cohort was discharged on a statin, but only 35% were prescribed the intensity of therapy recommended in the 2013 guidelines. Adherence was significantly higher in the cohort of patients older than 75 years, in which 55% were on the recommended intensity, compared with only 20% of those younger than 75 years (Fig) . The use of high-intensity statins in patients younger than 75 years nearly doubled after the introduction of the guidelines in 2013 (18% to 33%). However, use of moderate-intensity statin therapy in those older than 75 years remained unchanged (56% vs 53%), probably because of a concomitant doubling of high-intensity statin use from 14% to 29%.
Univariate analysis
Postoperative statin use compared with no statin. On univariate analysis, patients discharged on a statin had significantly higher 5-year survival, with 85% (95% confidence interval [CI], 82%-88%) alive at 1 year, 65% (60%-69%) at 3 years, and 41% (35%-46%) at 5 years compared with 82% (76%-87%), 55% (47%-62%), and 35% (26%-43%) of those not taking a statin (log-rank, P ¼ .02). There was no difference in the rate of MALE (P ¼ .21).
Intensity of statin therapy in accordance with 2013 lipid management guidelines. We also compared those patients on the intensity of statin therapy recommended by the ACC/AHA guidelines and those not prescribed the recommended intensity or not taking statins. Patients on recommended statin intensity had lower 5-year survival, with 84% (80%-88%) alive at 1 year, 58% (51%-64%) at 3 years, and 31% at 5 years compared with 84% (82%-88%), 65% (60%-69%), and 43% (38%-49%) of those not on recommended intensities (log-rank, P ¼ .01). There was no statistically significant difference in the rate of MALE (P ¼ .07).
Multivariable analysis
Postoperative statin use compared with no statin. After adjustment for age, sex, race, hypertension, diabetes, coronary artery disease, chronic kidney disease, smoking, procedure year, and indication, those patients discharged on a statin experienced a 29% lower rate of death (hazard ratio [HR], 0.71; 95% confidence interval, 0.60-0.90; P < .01; Table III ). This benefit was consistent in the subgroup of patients older than 75 years and those younger than 75 years (P for interaction ¼ 0.54). There was no difference in the rate of MALE (HR, 0.81; 95% CI, 0.60-1.09; P ¼ .16).
Intensity of statin therapy in accordance with 2013 lipid management guidelines. After adding the propensity score to our multivariable model to account for nonrandom assignment of treatment, patients on the intensity of statin therapy recommended by the 2013 lipid management guidelines experienced a 23% lower rate of death compared with other statin intensities (HR, 0.77; 95% CI, 0.60-0.99; P ¼ .04). The rate of MALE was also significantly lower in the patients on the recommended intensity of statin therapy (HR, 0.71; 95% CI, 0.51-0.97; P ¼ .03; Table IV ). There was no significant difference in this association between the subgroups of patients older and younger than 75 years (P > .1). We also found no difference in this association between patients who High-intensity vs moderate-intensity statin therapy in elderly patients. High-intensity statins were prescribed to 67 patients older than 75 years (15%), and moderateintensity statins were prescribed to 243 (55%). Of those prescribed a high-intensity statin postoperatively, 80% were taking a high-intensity statin preoperatively, 8% were taking a moderate-intensity statin, and 12% were not taking a statin. In unadjusted analysis, patients >75 years old taking moderate-intensity statins experienced higher rates of death (log-rank, P < .01). After adjustment, there was no statistically significant association with the rates of death and MALE between patients taking the recommended moderate-intensity statins and those on high-intensity therapy (death: HR, 0.79; 95% CI, 0.49-1.26, P ¼ .32; MALE: HR, 0.82; 95% CI, 0.41-1.64, P ¼ .58; Table V) .
Sensitivity analyses
The primary analysis was rerun after assigning patients taking simvastatin 80 mg to the high-intensity therapy group, and there was no difference in any of the observed associations. As this was a single-center study, differential loss to follow-up between treatment arms could bias our results. However, there was no association between loss to follow-up and intensity of statin therapy (P ¼ .64).
DISCUSSION
Our study demonstrates that statin therapy in accordance with the 2013 ACC/AHA guidelines is associated with significantly lower rates of death and limb events in patients undergoing first-time revascularization for a Adjusted for propensity score (continuous) and age, sex, race, hypertension, diabetes, coronary artery disease, chronic kidney disease, smoking, procedure year, and indication.
CLTI. Our findings are consistent with those of prior reports, which document the benefits of statins and the intensity of therapy recommended by the ACC/ AHA guidelines in other populations and validate them in the CLTI population. 9 In our study, statin use was associated with lower mortality by almost a third. This is similar to the findings of De Martino et al, 11 who showed that patients in the VQI discharged on a statin experienced a 20% decrease in mortality compared with those who were not (HR, 0.8; 95% CI, 0.7-0.9; P ¼ .01). However, that study was a heterogeneous cohort that included vascular patients undergoing a variety of procedures (lower extremity revascularization, carotid revascularization, and aortic aneurysm repair), with comparatively low rates of adequate medical therapy. In 2014, the last year of their study, only 62% of their cohort was taking both an antiplatelet agent and a statin. In our study, the rates of statin and antiplatelet use were higher. In 2014, 90% of our patients were taking a statin and 94% were taking an antiplatelet agent, and in the entire cohort, 77% were discharged on a statin and 93% on an antiplatelet agent. Our data demonstrate that although patients benefit from being prescribed a statin, they benefit even more if that statin is the recommended intensity. Patients who were prescribed the guideline-recommended intensity of statin experienced a 23% lower rate of death and 29% lower rate of MALE than those who were not treated in accordance with the guidelines. This is consistent with prior reports in other atherosclerotic disorders, as a substantial body of evidence including randomized, controlled trials demonstrates the importance of statin dose in both cerebrovascular and coronary populations. [13] [14] [15] Despite rates of medical therapy including statin use that were higher than in many previous studies, event rates in this vulnerable population remain extremely high, with only about a third of the population alive at 5 years. These data suggest that to bridge that gap, clinicians must consider not only if a patient is taking a statin but which statin and at what dose. The subset of patients older than 75 years represents an important subgroup that has not been well characterized. The ACC/AHA Panel concluded that there was adequate evidence to support the use of moderateintensity statins in this population but inadequate data to support the use of high-intensity therapy. 9 Establishing the most beneficial intensity of therapy in this population is of paramount importance as the population ages. Elderly patients may stand to benefit the most from high-intensity therapy, given their higher burden of comorbid conditions, but conversely may be more likely to discontinue their statin because of intolerance or side effects. Our data demonstrate a trend toward higher rates of death and limb events in elderly patients taking high-intensity statins. This could be due to random variation as our results are not statistically significant, or it could be due to other confounding variables we failed to control for. This cohort was a smaller subset, and thus we may have failed to detect a difference because of inadequate power. Those patients may have initially been prescribed higher doses because they are a higher risk cohort, although the fact that patients taking moderate-intensity statins actually had higher mortality in unadjusted analysis suggests the opposite conclusion. This population represents an important target for further research. These data must be interpreted in the context of the study design. We lack detailed records on compliance of patients with their prescribed statin therapy or changes in their doses over time, and statin compliance has been as low as 39% in some studies. 16, 17 Recent efforts, such as Get With The Guidelines, seek to improve these results, but their success in our population is unknown. 18 Further efforts could examine strategies to improve compliance as well as to determine whether more intensive statin therapy affects rates of compliance. This is a single-center study, and as such these results and the rates of adherence to guidelines may not be generalizable to the population at large. In addition, we may fail to capture all outcomes that may have occurred elsewhere, and we did not ascertain cause of death. However, this is unlikely to significantly bias our results, given our low rate of loss to follow-up (8%) and the lack of association between loss to follow-up and intensity of statin therapy. Future efforts could include performing similar analyses using nationally representative, multicenter data. The primary aim of our study was not to assess the adherence to these guidelines, especially before their publication, but rather to study the potential impact of their primary goal: treating high-risk populations with targeted statin intensities. Our findings present an important opportunity for multidisciplinary quality improvement. These data support the implementation of the recent guidelines in the CLTI population but also demonstrate that a substantial gap still exists in their implementation. The CLTI population is a vulnerable cohort that is served by a wide spectrum of clinicians from primary care providers, cardiologists, and interventionalists to vascular surgeons. Educating these diverse physicians about the benefits of following these guidelines represents an important opportunity to improve the care we provide this high-risk population of patients.
CONCLUSIONS
We found that statins are associated with significantly improved overall survival and lower limb events in patients undergoing revascularization for CLTI. Use of the recommended intensity of statin therapy in compliance with 2013 ACC/AHA lipid management guidelines provides important incremental benefit. Although adherence is increasing, 60% of eligible patients in our institution were not receiving recommended doses even in 2014, an appealing target for future quality improvement projects. 
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